Document Detail


Changes in food reward following smoking cessation: a pharmacogenetic investigation.
MedLine Citation:
PMID:  15138759     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
RATIONALE: Despite the high prevalence and public health significance of weight gain following smoking cessation, little is known about the underlying bio-behavioral mechanisms or effective therapies.
OBJECTIVES: We evaluated the effects of bupropion on food reward following smoking abstinence and the moderating influence of genotype.
METHODS: Seventy-one smokers of European ancestry were genotyped for the dopamine D2 receptor ( DRD2) Taq1 polymorphism and randomized to treatment with bupropion (300 mg) or placebo for smoking cessation. Subjects participated in two behavioral laboratory sessions during which the rewarding value of food was assessed using a behavioral economics measure: session 1 occurred prior to medication and before cessation of smoking; session 2 occurred following 3 weeks of medication and 1 week of sustained abstinence.
RESULTS: Carriers of the DRD2 A1 minor allele exhibited significant increases in the rewarding value of food following abstinence from smoking, and these effects were attenuated by bupropion treatment ( P=0.03 for medication by genotype interaction). Further, higher levels of food reward at session 2 (post-quit) predicted a significant increase in weight by 6-month follow-up in the placebo group, but not in the bupropion-treated group ( P=0.006 for medication by food reward interaction).
CONCLUSIONS: These results provide new evidence that the increase in body weight that occurs following smoking cessation is related to increases in food reward, and that food reward is partly determined by genetic factors. Bupropion's efficacy in attenuating abstinence-induced weight gain may be attributable, in part, to decreasing food reward.
Authors:
Caryn Lerman; Wade Berrettini; Angela Pinto; Freda Patterson; Susan Crystal-Mansour; E Paul Wileyto; Stephanie L Restine; Debra G B Leonard; Peter G Shields; Leonard H Epstein
Related Documents :
15619119 - Effects of deletion of gria1 or gria2 genes encoding glutamatergic ampa-receptor subuni...
19172379 - Distribution of potential suitable hammers and transport of hammer tools and nuts by wi...
12209569 - Comparison of responses to alarm calls by patas (erythrocebus patas) and vervet (cercop...
20361989 - Neurobiology of hyperactivity and reward: agreeable restlessness in anorexia nervosa.
19520119 - Similar hand shaping in reaching-for-food (skilled reaching) in rats and humans provide...
22567099 - Genetic variation of an odorant receptor or7d4 and sensory perception of cooked meat co...
24963759 - Household food insecurity: a systematic review of the measuring instruments used in epi...
6901189 - Taste preferences of infants for sweetened or unsweetened foods.
15619119 - Effects of deletion of gria1 or gria2 genes encoding glutamatergic ampa-receptor subuni...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.     Date:  2004-04-27
Journal Detail:
Title:  Psychopharmacology     Volume:  174     ISSN:  0033-3158     ISO Abbreviation:  Psychopharmacology (Berl.)     Publication Date:  2004 Aug 
Date Detail:
Created Date:  2004-08-04     Completed Date:  2004-12-02     Revised Date:  2014-03-25    
Medline Journal Info:
Nlm Unique ID:  7608025     Medline TA:  Psychopharmacology (Berl)     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  571-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Bupropion / therapeutic use*
Case-Control Studies
Dopamine Uptake Inhibitors / therapeutic use*
Double-Blind Method
European Continental Ancestry Group / genetics
Female
Food
Humans
Male
Middle Aged
Pharmacogenetics
Polymorphism, Genetic
Receptors, Dopamine D2 / classification,  genetics
Reward
Smoking / drug therapy*,  psychology
Smoking Cessation / ethnology,  methods*
Treatment Outcome
Grant Support
ID/Acronym/Agency:
P50 CA/DA 84718/CA/NCI NIH HHS; R01 CA 63562/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Dopamine Uptake Inhibitors; 0/Receptors, Dopamine D2; 01ZG3TPX31/Bupropion

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Corticotropin-releasing factor overexpression decreases ethanol drinking and increases sensitivity t...
Next Document:  Methylphenidate restores visual memory, but not working memory function in attention deficit-hyperki...